BiotechTube

Aripiprazole + Placebo

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Irritability Associated With Autistic Disorder

Conditions

Irritability Associated With Autistic Disorder

Trial Timeline

Mar 1, 2011 → Jun 1, 2012

NCT ID
NCT01227668

About Aripiprazole + Placebo

Aripiprazole + Placebo is a approved stage product being developed by Bristol Myers Squibb for Irritability Associated With Autistic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01227668. Target conditions include Irritability Associated With Autistic Disorder.

What happened to similar drugs?

0 of 4 similar drugs in Irritability Associated With Autistic Disorder were approved

Approved (0) Terminated (0) Active (4)
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
🔄Brexpiprazole + PlaceboLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01227668ApprovedCompleted
NCT00194077Phase 3Completed
NCT00194012Phase 3Completed

Competing Products

7 competing products in Irritability Associated With Autistic Disorder

See all competitors
ProductCompanyStageHype Score
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
Brexpiprazole + PlaceboLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
JZP541Jazz PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2/3
27
Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 2/3
35